| Pharmaceutics: The science of dosage form design ME Aulton (No Title), 2002 | 2965 | 2002 |
| Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates N Blagden, M de Matas, PT Gavan, P York Advanced drug delivery reviews 59 (7), 617-630, 2007 | 1759 | 2007 |
| Solubility parameters as predictors of miscibility in solid dispersions DJ Greenhalgh, AC Williams, P Timmins, P York Journal of pharmaceutical sciences 88 (11), 1182-1190, 1999 | 746 | 1999 |
| Crystallization processes in pharmaceutical technology and drug delivery design BY Shekunov, P York Journal of crystal growth 211 (1-4), 122-136, 2000 | 567 | 2000 |
| Process control and scale-up of pharmaceutical wet granulation processes: a review A Faure, P York, RC Rowe European Journal of Pharmaceutics and Biopharmaceutics 52 (3), 269-277, 2001 | 453 | 2001 |
| The use of solubility parameters in pharmaceutical dosage form design BC Hancock, P York, RC Rowe International journal of pharmaceutics 148 (1), 1-21, 1997 | 386 | 1997 |
| Strategies for particle design using supercritical fluid technologies P York Pharmaceutical science & technology today 2 (11), 430-440, 1999 | 366 | 1999 |
| Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling HSM Ali, P York, AMA Ali, N Blagden Journal of controlled release 149 (2), 175-181, 2011 | 299 | 2011 |
| Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors HSM Ali, P York, N Blagden International journal of pharmaceutics 375 (1-2), 107-113, 2009 | 289 | 2009 |
| Solid-state properties of powders in the formulation and processing of solid dosage forms P York International Journal of Pharmaceutics 14 (1), 1-28, 1983 | 283 | 1983 |
| Cocrystalization and simultaneous agglomeration using hot melt extrusion RS Dhumal, AL Kelly, P York, PD Coates, A Paradkar Pharmaceutical research 27, 2725-2733, 2010 | 252 | 2010 |
| Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronisation JC Feeley, P York, BS Sumby, H Dicks International journal of pharmaceutics 172 (1-2), 89-96, 1998 | 243 | 1998 |
| Phase behavioral effects on particle formation processes using supercritical fluids S Palakodaty, P York Pharmaceutical research 16, 976-985, 1999 | 229 | 1999 |
| Crystal engineering and particle design for the powder compaction process P York Drug development and industrial pharmacy 18 (6-7), 677-721, 1992 | 210 | 1992 |
| Method and apparatus for the formation of particles M Hanna, P York US Patent 6,063,138, 2000 | 185 | 2000 |
| Moisture induced polymorphic transition of mannitol and its morphological transformation T Yoshinari, RT Forbes, P York, Y Kawashima International journal of pharmaceutics 247 (1-2), 69-77, 2002 | 183 | 2002 |
| Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability RS Dhumal, SV Biradar, S Yamamura, AR Paradkar, P York European Journal of Pharmaceutics and Biopharmaceutics 70 (1), 109-115, 2008 | 182 | 2008 |
| Optimisation of the predictive ability of artificial neural network (ANN) models: a comparison of three ANN programs and four classes of training algorithm AP Plumb, RC Rowe, P York, M Brown European Journal of Pharmaceutical Sciences 25 (4-5), 395-405, 2005 | 174 | 2005 |
| Analysis of the surface energy of pharmaceutical powders by inverse gas chromatography IM Grimsey, JC Feeley, P York Journal of pharmaceutical sciences 91 (2), 571-583, 2002 | 172 | 2002 |
| Particle formation by mixing with supercritical antisolvent at high Reynolds numbers BY Shekunov, J Baldyga, P York Chemical Engineering Science 56 (7), 2421-2433, 2001 | 164 | 2001 |
